Comparative analysis of the performance of hepatobiliary agents in depicting MRI features of microvascular infiltration in hepatocellular carcinoma
- PMID: 38824474
- DOI: 10.1007/s00261-024-04311-x
Comparative analysis of the performance of hepatobiliary agents in depicting MRI features of microvascular infiltration in hepatocellular carcinoma
Abstract
Objective: To compare the ability to depict MRI features of hepatobiliary agents in microvascular infiltration (MVI) of hepatocellular carcinoma (HCC) during different stages of dynamic enhancement MRI.
Materials and methods: A retrospective study included 111 HCC lesions scanned with either Gd-EOB-DTPA or Gd-BOPTA. All cases underwent multiphase dynamic contrast-enhanced scanning before surgery, including arterial phase (AP), portal venous phase (PVP), transitional phase (TP), delayed phase (DP), and hepatobiliary phase (HBP). Two abdominal radiologists independently evaluated MRI features of MVI in HCC, such as peritumoral hyperenhancement, incomplete capsule, non-smooth tumor margins, and peritumoral hypointensity. Finally, the results were reviewed by the third senior abdominal radiologist. Chi-square (χ2) Inspection for comparison between groups. P < 0.05 is considered statistically significant. Receiver operating characteristic (ROC) curve was used to evaluate correlation with pathology, and the area under the curve (AUC) and 95% confidence interval (95% CI) were calculated.
Results: Among the four MVI evaluation signs, Gd-BOPTA showed significant differences in displaying two signs in the HBP (P < 0.05:0.000, 0.000), while Gd-EOB-DTPA exhibited significant differences in displaying all four signs (P < 0.05:0.005, 0.006, 0.000, 0.002). The results of the evaluations of the two contrast agents in the DP phase with incomplete capsulation showed the highest correlation with pathology (AUC: 0.843, 0.761). By combining the four MRI features, Gd-BOPTA and Gd-EOB-DTPA have correlated significantly with pathology, and Gd-BOPTA is better (AUC: 0.9312vs0.8712).
Conclusion: The four features of hepatobiliary agent dynamic enhancement MRI demonstrate a good correlation with histopathological findings in the evaluation of MVI in HCC, and have certain clinical significance.
Keywords: Gd-BOPTA; Gd-EOB-DTPA; Hepatocellular carcinoma; Microvascular infiltration.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Comparison of the Ability of Gadobenate Dimeglumine and Gadolinium Ethoxybenzyl Dimeglumine to Display the major Features for Noninvasively Diagnosing Hepatocellular Carcinoma According to the LI-RADS 2018v.Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241260331. doi: 10.1177/15330338241260331. Technol Cancer Res Treat. 2024. PMID: 38860337 Free PMC article.
-
The value of the signal intensity of peritumoral tissue on Gd-EOB-DTPA dynamic enhanced MRI in assessment of microvascular invasion and pathological grade of hepatocellular carcinoma.Medicine (Baltimore). 2021 May 21;100(20):e25804. doi: 10.1097/MD.0000000000025804. Medicine (Baltimore). 2021. PMID: 34011043 Free PMC article.
-
Imaging Features of Hepatocellular Carcinoma: Quantitative and Qualitative Comparison Between MRI-Enhanced With Gd-EOB-DTPA and Gd-DTPA.Invest Radiol. 2019 Aug;54(8):494-499. doi: 10.1097/RLI.0000000000000562. Invest Radiol. 2019. PMID: 31094878
-
Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.Eur Radiol. 2020 Oct;30(10):5348-5357. doi: 10.1007/s00330-020-06923-5. Epub 2020 May 13. Eur Radiol. 2020. PMID: 32405753
-
Peritumoral Imaging Manifestations on Gd-EOB-DTPA-Enhanced MRI for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Front Oncol. 2022 Jun 24;12:907076. doi: 10.3389/fonc.2022.907076. eCollection 2022. Front Oncol. 2022. PMID: 35814461 Free PMC article.
References
-
- Frick Clara,Rumgay Harriet,Vignat Jérôme et al. Quantitative estimates of preventable and treatable deaths from 36 cancers worldwide: a population-based study.[J] .Lancet Glob Health, 2023, 11: e1700-e1712. - DOI
-
- Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245-1255. https://doi.org/10.1016/S0140-6736(11)61347-0 - DOI - PubMed
-
- Raoul JL, Edeline J. Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere. Lancet Oncol. 2020;21(4):479-481. https://doi.org/10.1016/S1470-2045(20)30082-6 - DOI - PubMed
-
- Wang W, Yang C, Zhu K, et al. Recurrence after Curative Resection of HBV-related Hepatocellular Carcinoma: Diagnostic Algorithms on Gadoxetic Acid-enhanced MRI. Liver Transplantation, 2020, 26(6):751-763. - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous